3,4-dimethylmethcathinone: a designer drug; structure in first source
ID Source | ID |
---|---|
PubMed CID | 52988261 |
CHEBI ID | 189377 |
MeSH ID | M000602329 |
Synonym |
---|
3,4-dmmc |
1-(3,4-dimethylphenyl)-2-(methylamino)propan-1-one |
CHEBI:189377 |
3,4-dimethylmethcathinone |
3,4-dimethylmethcathinone hydrochloride |
3,4-dmmc hcl |
IBZRXTVDTGVBIS-UHFFFAOYSA-N |
1-propanone, 1-(3,4-dimethylphenyl)-2-(methylamino)- |
C4EW58DTW5 , |
1082110-00-6 |
(+/-)-1-(3,4-dimethylphenyl)-2-(methylamino)propan-1-one |
J3.065.113H , |
unii-c4ew58dtw5 |
1-(3,4-dimethylphenyl)-2-methylaminopropan-1-one |
Q4634067 |
DTXSID501016968 |
PD048189 |
Excerpt | Reference | Relevance |
---|---|---|
" Importantly, NAC was also able to prevent the cytotoxicity promoted by 6 tested drugs, ruling for an involvement of oxidative stress in the toxic events observed." | ( Structure-cytotoxicity relationship profile of 13 synthetic cathinones in differentiated human SH-SY5Y neuronal cells. Capela, JP; Carvalho, F; Costa, VM; de Lourdes Bastos, M; Gaspar, H; Santos, S; Soares, J, 2019) | 0.51 |
Class | Description |
---|---|
aromatic ketone | A ketone in which the carbonyl group is attached to an aromatic ring. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (33.33) | 24.3611 |
2020's | 4 (66.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (37.96) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 1 (16.67%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (83.33%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |